If you are an external healthcare provider with no access to Nationwide Children's Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children's Epic system, no requisition form is required; please place the lab order electronically in Epic. Please send all samples via overnight delivery. Saturday deliveries are accepted; please check Saturday Delivery on shipment label.

If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.

For hematologic malignancies, submission of a sample containing at least 20% blasts is required. For solid tumor malignancies, submission of a sample containing at least 40% tumor is required. An internal pathology review will be performed on submitted samples to verify tumor/blast content. 

Oncology chromosomal microarray analysis is performed on the Affymetrix OncoScan(TM) CNV platform to detect clinically significant chromosomal aberrations and loss of heterozygosity (LOH) in the tumor and bone marrow/neoplastic blood specimens to aid in prognosis, diagnosis and/or treatment assessment. 

This test detects clinically significant chromosomal aberrations in the tumor and bone marrow/neoplastic blood specimens to aid in prognosis, diagnosis and/or treatment assessment. 

Examples of specific tumor assessments:

Neuroblastoma:

This test evaluates the following clinically significant aberrations within the cancer genome for Neuroblastoma as determined by the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN):

• Copy number loss of 1p, 3p, 4p and 11q
• Copy number gain of 1q, 2p and 17q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 3p, 4p and 11q
• MYCN and ALK gene amplification or copy gain
• Whole chromosome gains 

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

Wilms Tumor:

This test evaluates for the following clinically significant aberrations within the cancer genome for Wilms Tumor:

• Copy number loss of 1p, 11p13, 11p15, 16q, and 17p
• Copy number gain of 1q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 11p13, 11p15, 16q, and 17p

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

B-Acute Lymphoblastic Leukemia (B-ALL):

This test evaluates genome-wide clinically significant copy number aberrations and loss of heterozygosity including the following:

•           Intrachromosomal amplification of 21 (iAMP21)
•           Hyperdiploidy
•           Doubled hypodiploidy and haploidy
•           Deletions of clinically significant genes (e.g. IKZF1, ERG etc.)

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

PLEASE NOTE:

1. For solid tumor malignancies, at least 40% tumor must be present in the submitted tumor sample. For hematologic malignancies, at least 20% blasts must be present in the submitted bone marrow or neoplastic blood sample. An internal pathology review will be performed on submitted samples to verify tumor/blast content. 
2. Pre-treatment samples are preferred over post-treatment samples. If submitting a sample collected during or after treatment (e.g. post-chemotherapy), please indicate post-treatment status of the sample on the requisition form.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls, an H&E slide from a consecutive cut is also required Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required. Tissue blocks can be returned to the treating institution upon request.

If you are an external healthcare provider with no access to Nationwide Children's Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children's Epic system, no requisition form is required; please place the lab order electronically in Epic. Please send all samples via overnight delivery. Saturday deliveries are accepted; please check Saturday Delivery on shipment label.

If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.

For hematologic malignancies, submission of a sample containing at least 20% blasts is required. For solid tumor malignancies, submission of a sample containing at least 40% tumor is required. An internal pathology review will be performed on submitted samples to verify tumor/blast content. 

Oncology chromosomal microarray analysis is performed on the Affymetrix OncoScan(TM) CNV platform to detect clinically significant chromosomal aberrations and loss of heterozygosity (LOH) in the tumor and bone marrow/neoplastic blood specimens to aid in prognosis, diagnosis and/or treatment assessment. 

This test detects clinically significant chromosomal aberrations in the tumor and bone marrow/neoplastic blood specimens to aid in prognosis, diagnosis and/or treatment assessment. 

Examples of specific tumor assessments:

Neuroblastoma:

This test evaluates the following clinically significant aberrations within the cancer genome for Neuroblastoma as determined by the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN):

• Copy number loss of 1p, 3p, 4p and 11q
• Copy number gain of 1q, 2p and 17q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 3p, 4p and 11q
• MYCN and ALK gene amplification or copy gain
• Whole chromosome gains 

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

Wilms Tumor:

This test evaluates for the following clinically significant aberrations within the cancer genome for Wilms Tumor:

• Copy number loss of 1p, 11p13, 11p15, 16q, and 17p
• Copy number gain of 1q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 11p13, 11p15, 16q, and 17p

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

B-Acute Lymphoblastic Leukemia (B-ALL):

This test evaluates genome-wide clinically significant copy number aberrations and loss of heterozygosity including the following:

•           Intrachromosomal amplification of 21 (iAMP21)
•           Hyperdiploidy
•           Doubled hypodiploidy and haploidy
•           Deletions of clinically significant genes (e.g. IKZF1, ERG etc.)

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

PLEASE NOTE:

1. For solid tumor malignancies, at least 40% tumor must be present in the submitted tumor sample. For hematologic malignancies, at least 20% blasts must be present in the submitted bone marrow or neoplastic blood sample. An internal pathology review will be performed on submitted samples to verify tumor/blast content. 
2. Pre-treatment samples are preferred over post-treatment samples. If submitting a sample collected during or after treatment (e.g. post-chemotherapy), please indicate post-treatment status of the sample on the requisition form.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls, an H&E slide from a consecutive cut is also required Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required. Tissue blocks can be returned to the treating institution upon request.

This test detects clinically significant chromosomal aberrations in the tumor and bone marrow/neoplastic blood specimens to aid in prognosis, diagnosis and/or treatment assessment. 

Examples of specific tumor assessments:

Neuroblastoma:

This test evaluates the following clinically significant aberrations within the cancer genome for Neuroblastoma as determined by the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN):

• Copy number loss of 1p, 3p, 4p and 11q
• Copy number gain of 1q, 2p and 17q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 3p, 4p and 11q
• MYCN and ALK gene amplification or copy gain
• Whole chromosome gains 

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

Wilms Tumor:

This test evaluates for the following clinically significant aberrations within the cancer genome for Wilms Tumor:

• Copy number loss of 1p, 11p13, 11p15, 16q, and 17p
• Copy number gain of 1q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 11p13, 11p15, 16q, and 17p

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

B-Acute Lymphoblastic Leukemia (B-ALL):

This test evaluates genome-wide clinically significant copy number aberrations and loss of heterozygosity including the following:

•           Intrachromosomal amplification of 21 (iAMP21)
•           Hyperdiploidy
•           Doubled hypodiploidy and haploidy
•           Deletions of clinically significant genes (e.g. IKZF1, ERG etc.)

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

PLEASE NOTE:

1. For solid tumor malignancies, at least 40% tumor must be present in the submitted tumor sample. For hematologic malignancies, at least 20% blasts must be present in the submitted bone marrow or neoplastic blood sample. An internal pathology review will be performed on submitted samples to verify tumor/blast content. 
2. Pre-treatment samples are preferred over post-treatment samples. If submitting a sample collected during or after treatment (e.g. post-chemotherapy), please indicate post-treatment status of the sample on the requisition form.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls, an H&E slide from a consecutive cut is also required Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required. Tissue blocks can be returned to the treating institution upon request.

If you are an external healthcare provider with no access to Nationwide Children's Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children's Epic system, no requisition form is required; please place the lab order electronically in Epic. Please send all samples via overnight delivery. Saturday deliveries are accepted; please check Saturday Delivery on shipment label.

If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.

For hematologic malignancies, submission of a sample containing at least 20% blasts is required. For solid tumor malignancies, submission of a sample containing at least 40% tumor is required. An internal pathology review will be performed on submitted samples to verify tumor/blast content. 

Oncology chromosomal microarray analysis is performed on the Affymetrix OncoScan(TM) CNV platform to detect clinically significant chromosomal aberrations and loss of heterozygosity (LOH) in the tumor and bone marrow/neoplastic blood specimens to aid in prognosis, diagnosis and/or treatment assessment. 

This test detects clinically significant chromosomal aberrations in the tumor and bone marrow/neoplastic blood specimens to aid in prognosis, diagnosis and/or treatment assessment. 

Examples of specific tumor assessments:

Neuroblastoma:

This test evaluates the following clinically significant aberrations within the cancer genome for Neuroblastoma as determined by the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN):

• Copy number loss of 1p, 3p, 4p and 11q
• Copy number gain of 1q, 2p and 17q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 3p, 4p and 11q
• MYCN and ALK gene amplification or copy gain
• Whole chromosome gains 

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

Wilms Tumor:

This test evaluates for the following clinically significant aberrations within the cancer genome for Wilms Tumor:

• Copy number loss of 1p, 11p13, 11p15, 16q, and 17p
• Copy number gain of 1q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 11p13, 11p15, 16q, and 17p

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

B-Acute Lymphoblastic Leukemia (B-ALL):

This test evaluates genome-wide clinically significant copy number aberrations and loss of heterozygosity including the following:

•           Intrachromosomal amplification of 21 (iAMP21)
•           Hyperdiploidy
•           Doubled hypodiploidy and haploidy
•           Deletions of clinically significant genes (e.g. IKZF1, ERG etc.)

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

PLEASE NOTE:

1. For solid tumor malignancies, at least 40% tumor must be present in the submitted tumor sample. For hematologic malignancies, at least 20% blasts must be present in the submitted bone marrow or neoplastic blood sample. An internal pathology review will be performed on submitted samples to verify tumor/blast content. 
2. Pre-treatment samples are preferred over post-treatment samples. If submitting a sample collected during or after treatment (e.g. post-chemotherapy), please indicate post-treatment status of the sample on the requisition form.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls, an H&E slide from a consecutive cut is also required Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required. Tissue blocks can be returned to the treating institution upon request.